Ajanta Pharma gets USFDA observation for Paithan facility
New Delhi : Drug firm Ajanta Pharma said the US health regulator has issued one observation for its Paithan facility in Aurangabad after the inspection.
"This is to inform that our Paithan facility was recently inspected by the US FDA and we are issued one procedural related 483," Ajanta Pharma said in a BSE filing.
It further said: "We are in process of responding to the same within the stipulated time prescribed by US FDA."
Shares of Ajanta Pharma were trading 1.84 per cent higher at Rs 1,791.50 on the BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd